Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2019

View Archived Issues

BLU-5937: P2X3 homotrimeric receptor antagonist with improved taste safety profile for cough

Long-term data presented from FORWARD-2 study of ALKS-5461

NRD.E1 demonstrates promising safety and efficacy in proof-of-concept study

Results from first portion of phase I study of PRN-1371 in patients with solid tumors

Location, location, location: Looking between the lines leads to neurofibromatosis insight

A novel antagonistic CD73 antibody for cancer immunotherapy presented

Fruit fly avatars identify drug sensitivity

Flu virus makes bacteria stick around

NI-956, a new prodrug inhibitor of aminopeptidase A, shows promise for hypertension treatment

Discovery of a broad-spectrum human antibody to influenza A recognizing a new site of vulnerability

FDA approves Zolgensma for spinal muscular atrophy

MIDRIXneo, a personalized vaccine as adjuvant therapy for immune checkpoint blockade

Jakafi approved by FDA for steroid-refractory acute GvHD

Aclaris Therapeutics patents JAK1 and JAK3 inhibitors

ORIC Pharmaceuticals presents CD73 inhibitors

FDA approves Piqray for HR+/HER2-, PIK3CA-mutated advanced breast cancer

Zealand Pharma describes amylin and/or calcitonin receptor agonists

Nanjing CART Medical Technologies discloses CAR T cells for hematologic cancer

Alpine Immune Sciences divulges new fusion proteins

Sensorion signs hearing loss research partnership framework agreement with Institut Pasteur

PCI Biotech begins pivotal RELEASE study of fimaChem in inoperable bile duct cancer

Phase III study of Lyrica in PGTC seizures fails to meet primary endpoint

Genmab initiates phase I/IIa safety study of GEN-1046 in malignant solid tumors

OnKure begins new phase I trial of OKI-179 in solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...